Sarepta Therapeutic Given New $27.00 Price Target at Canaccord Genuity (SRPT)

Share on StockTwits

Stock analysts at Canaccord Genuity raised their price target on shares of Sarepta Therapeutic (NASDAQ:SRPT) from $25.00 to $27.00 in a report issued on Tuesday, AnalystRatings.Net reports. The firm currently has a “hold” rating on the stock. Canaccord Genuity’s target price indicates a potential downside of 10.86% from the company’s current price. The analysts noted that the move was a valuation call.

A number of other analysts have also recently weighed in on SRPT. Analysts at JMP Securities downgraded shares of Sarepta Therapeutic from an “outperform” rating to a “market perform” rating in a research note on Monday, January 27th. They now have a $25.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Needham & Company upgraded shares of Sarepta Therapeutic from a “hold” rating to a “buy” rating in a research note on Tuesday, January 21st. They now have a $36.00 price target on the stock. Finally, analysts at Citigroup Inc. downgraded shares of Sarepta Therapeutic from a “neutral” rating to a “sell” rating in a research note on Monday, January 6th. They now have a $13.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $28.08.

Sarepta Therapeutic (NASDAQ:SRPT) traded down 2.28% on Tuesday, hitting $29.60. The stock had a trading volume of 322,399 shares. Sarepta Therapeutic has a 52-week low of $12.12 and a 52-week high of $55.61. The stock has a 50-day moving average of $26.62 and a 200-day moving average of $30.05. The company’s market cap is $1.113 billion.

Sarepta Therapeutic (NASDAQ:SRPT) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.77) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.69) by $0.08. The company had revenue of $2.60 million for the quarter, compared to the consensus estimate of $4.53 million. During the same quarter in the prior year, the company posted ($2.36) earnings per share. The company’s quarterly revenue was down 64.4% on a year-over-year basis. Analysts expect that Sarepta Therapeutic will post $-3.17 EPS for the current fiscal year.

Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of both rare and infectious diseases.

Receive News & Ratings for Sarepta Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutic and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Seadrill Stock Rating Upgraded by RS Platou
Seadrill Stock Rating Upgraded by RS Platou
Steven Madden Rating Reiterated by Wunderlich
Steven Madden Rating Reiterated by Wunderlich
Vitae Pharmaceuticals Research Coverage Started at Stifel Nicolaus
Vitae Pharmaceuticals Research Coverage Started at Stifel Nicolaus
Vitae Pharmaceuticals Earns Outperform Rating from Analysts at BMO Capital Markets
Vitae Pharmaceuticals Earns Outperform Rating from Analysts at BMO Capital Markets
Yahoo! Stock Rating Reaffirmed by Pivotal Research
Yahoo! Stock Rating Reaffirmed by Pivotal Research
Analysts’ Ratings Reiterations for October, 21st
Analysts’ Ratings Reiterations for October, 21st


Leave a Reply

 
Advertisement
Advertisement
© 2006-2014 Mideast Time.